Sugi Predict

Sugi Predict / Compounds / SCHEMBL143722

SCHEMBL143722

SCHEMBL143722

COC(=O)c1cc(Br)nc2c1[nH]c1ccc(C=O)cc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 4/20 0.38
▸ MPL P40238 1/20 0.38
▸ ALDH1A1 P00352 4/20 0.37
▸ MAPT P10636 3/20 0.37
▸ HPGD P15428 3/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ TP53 P04637 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ KIF11 P52732 1/20 0.37
▸ PIM1 P11309 2/20 0.37
▸ PIM3 Q86V86 2/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ GABRP O00591 1/20 0.35
▸ GABRD O14764 1/20 0.35
▸ GABRA1 P14867 1/20 0.35
▸ GABRB1 P18505 1/20 0.35
▸ GABRG2 P18507 1/20 0.35
▸ GABRB3 P28472 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL137418 0.91 JAK2 (0.41) NR4A2MPLALDH1A1MAPTHPGD
SCHEMBL144182 0.86 KIF11 (0.40) MPLALDH1A1KDM4ELMNAHSD17B10
SCHEMBL145786 0.78 JAK2 (0.43) NR4A2MPLALDH1A1MAPTHPGD
SCHEMBL145169 0.77 NR4A2 (0.51) NR4A2MPLHPGDKDM4ELMNA
SCHEMBL138263 0.77 JAK2 (0.57) NR4A2ALDH1A1MAPTHPGDKDM4E
SCHEMBL141121 0.77 JAK2 (0.42) NR4A2MPLALDH1A1MAPTHPGD
SCHEMBL144397 0.76 JAK2 (0.54) KDM4EMAPK1SMN1; SMN2JAK2HTT
SCHEMBL141841 0.75 ALDH1A1 (0.40) ALDH1A1MAPTHPGDKDM4ELMNA
SCHEMBL6626500 0.75 PIM1 (0.58) NR4A2MPLALDH1A1MAPTHPGD
SCHEMBL140995 0.74 JAK2 (0.51) KMT2AJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 — — US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 — — US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 — — EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 — — US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 — — US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 — — EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 NR4A2 2585/4885MPL 221/4885ALDH1A1 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.